NewcelX Ltd. Ordinary Shares (NCEL)

FairStock Score: 23/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

NewcelX is a $22.7 million micro-cap biotech with nine employees and no long filing history. At the 2026-10-26 close of $2.55, FairStock's P/E is 4.90 and P/B is 2.28, which looks statistically cheap on earnings but not on book value. The FairStock Graham Number is $3.62, implying a 26.52% margin of safety, yet I do not treat that as a durable bargain when the quality evidence is so thin. The company reports ROCE of -49.59%, so capital is not earning a positive return. It has low leverage with D/E of 0.06, which helps, but the FairStock Piotroski F-score is 1/9 and Altman Z-score is -322.65—both point to fragile financial signals. FairStock's overall score is 23/100. I cannot assess revenue or profit growth because the supplied growth figures are N/A, and the company has only 0 years of filed results; FairStock's Lynch category is none because it needs three years. That lack of history matters more than a low P/E. The business describes promising stem-cell-derived therapies for diabetes and neurodegenerative disease, but I see no moat in the numbers, no dividend, and no demonstrated operating record. The stock's 52-week range of $1.83 to $12.10 shows how volatile the market's view is. I would want evidence of durable positive returns, better financial scoring, and a multi-year record before calling this a high-quality value opportunity rather than a statistically cheap but speculative micro-cap.

In plain English: NewcelX is a very small biotech company with 9 employees that is trying to develop stem-cell treatments for diabetes and nerve diseases. The figures show a weak business: it has little filing history, negative returns on the capital it uses, and poor financial-health scores. The share price looks cheap against one simple value estimate, but the overall picture is not clearly cheap given the weak quality.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer